Dr. Kamaljit Kaur

Kamaljit Kaur received her Ph.D. in Bioorganic Chemistry from Case Western Reserve University (Cleveland, Ohio). She was a postdoctoral fellow at Wesleyan University (Connecticut) before moving to the University of Alberta (Canada), where she joined the Faculty of Pharmacy and Pharmaceutical Sciences as an Assistant Professor of Medicinal Chemistry in 2004.  In 2014, she moved to Chapman University (Irvine, California) as a Distinguished Chancellor Fellow, transitioning to a full-time role as a founding member of the Chapman University School of Pharmacy faculty in 2015.  Her researchfocuses on engineering peptides for biomedical applications and elucidating their mechanisms of action.  Current ongoing projects in her lab include (i) Peptide-drug conjugates (PDCs) to maximize the efficacy and safety of chemotherapy for cancer treatment, (ii) Conjugates for targeted drug delivery to the brain for Alzheimer’s Disease (AD) treatment, and (iii) Antimicrobial Peptides (AMPs) against pathogenic Gram-positive and Gram-negative multi-drug resistant (MDR) bacteria.

Kaur has published over 75 peer-reviewed articles (h-index = 40), four book chapters, has been listed as an inventor in 3 approved patents, and has presented in more than 35 invited talks.  She serves on the review panel of several granting agencies, including the National Institutes of Health (NIH) and the Canadian Institutes of Health Research (CIHR).  She is currently an editorial board member for the journals Scientific Reports and Pharmaceutics, and serves on the American Chemical Society (ACS) Division of Medicinal Chemistry - Long Range Planning Committee (LRPC).